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Abstract
In our previous study, we demonstrated the propagation of mouse-passaged scrapie iso-
lates with long incubation periods (L-type) derived from natural Japanese sheep scrapie
cases in murine hypothalamic GT1-7 cells, along with disease-associated prion protein
(PrPSc) accumulation. We here analyzed the susceptibility of GT1-7 cells to scrapie prions
by exposure to infected mouse brains at different passages, following interspecies transmis-
sion. Wild-type mice challenged with a natural sheep scrapie case (Kanagawa) exhibited
heterogeneity of transmitted scrapie prions in early passages, and this mixed population
converged upon one with a short incubation period (S-type) following subsequent passages.
However, when GT1-7 cells were challenged with these heterologous samples, L-type
prions became dominant. This study demonstrated that the susceptibility of GT1-7 cells to
L-type prions was at least 105 times higher than that to S-type prions and that L-type prion-
specific biological characteristics remained unchanged after serial passages in GT1-7 cells.
This suggests that a GT1-7 cell culture model would be more useful for the economical and
stable amplification of L-type prions at the laboratory level. Furthermore, this cell culture
model might be used to selectively propagate L-type scrapie prions from a mixed prion
population.
Introduction
Scrapie is a transmissible spongiform encephalopathy (TSE) of sheep and goats. TSE, also
known as prion disease, is a family of fatal neurodegenerative disorders that affect both
humans and animals [1]. The diversity of scrapie prions in sheep has been well investigated
[2–6]. Currently, it has believed that sheep scrapie consists of more than 20 strains with differ-
ent biological phenotypes, including different incubation periods; lesion profiles; biochemical
PLOS ONE | https://doi.org/10.1371/journal.pone.0179317 June 21, 2017 1 / 14
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Miyazawa K, Masujin K, Okada H, Ushiki-
Kaku Y, Matsuura Y, Yokoyama T (2017) Selective
propagation of mouse-passaged scrapie prions
with long incubation period from a mixed prion
population using GT1-7 cells. PLoS ONE 12(6):
e0179317. https://doi.org/10.1371/journal.
pone.0179317
Editor: Christopher James Johnson, US Geological
Survey, UNITED STATES
Received: January 21, 2017
Accepted: May 26, 2017
Published: June 21, 2017
Copyright: © 2017 Miyazawa et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: K. Miyazawa received the Grants-in-Aid
from the Ministry of Health, Labor, and Welfare of
Japan. K. Miyazawa, K. Masujin, HO, YM and TY
received the basic research fund of National
Agriculture and Food Research Organization
(NARO).
properties of the disease-associated prion protein (PrPSc), a misfolded form of the cellular
prion protein (PrPC); and neuroanatomical PrPSc distribution patterns in inbred mice [7–9].
Thus far, there have been no reports of scrapie prions being transmitted to humans. However,
a panel of scrapie prions can be transmitted to several lines of transgenic mice overexpressing
human PrPC [10]. More recently, scrapie prions were successfully transmitted to primates
[11]. Thus, it is important to distinguish and analyze the biological and pathological differ-
ences among scrapie prions to determine whether any exhibit zoonotic potential.
We previously reported that two different mouse-passaged scrapie prion types were isolated
from a single natural scrapie case (Kanagawa) of sheep by interspecies transmission to mice
[4]. These isolates were designated as short-type (S-type) and long-type (L-type) based on their
incubation periods and pathologies [4, 5]. Further, we reported that murine hypothalamic
GT1-7 cells produced de novo PrPSc in response to L-type prions but not to S-type prions [5].
In this study, we demonstrated through mouse bioassays that the biological properties of L-
type prions remained unchanged even after serial passages in GT1-7 cells. Our data suggest
that GT1-7 cells can be used to selectively propagate L-type scrapie prions from a mixed prion
population during the early transmission of sheep scrapie prions to mouse.
Materials and methods
Mouse-passaged sheep scrapie prions in this study
Three mouse-passaged field scrapie prion isolates (Tsukuba-2, Ka/O, and Ka/W) [3, 4] were
used in this study. ICR/CD-1 mice infected with L-type prion isolates (Tsukuba-2 and Ka/O)
exhibit clinical symptoms of polydipsia and polyuria with a long incubation period (approxi-
mately 280 days) and restricted PrPSc distribution in the brain stem [3, 5]. In contrast, mice
infected with the S-type prion isolate (Ka/W) exhibit a short incubation period (approximately
150 days) and marked vacuolation and PrPSc distribution throughout the entire brain area [4].
Mouse inoculation
Animal experiments were carried out in strict accordance with the regulations outlined in the
Guide for the Care and Use of Laboratory Animals of the National Institute of Animal Health
(NIAH) and Guidelines for Proper Conduct of Animal Experiments, 2006 by the Science
Council of Japan. All animal experiments were performed with the approval of the Animal
Ethical Committee and the Animal Care and Use Committee of the NIAH (approval ID:
11–008 and 15–005). For the primary passage, the brain stem of a scrapie affected sheep (Kana-
gawa) was intracerebrally inoculated into mice (n = 16) as described in our previous report
[4]. Two out of the 16 mice were chosen for the secondary passage (referred as Mo1 of Exp. 1
and Mo10 of Exp. 2 in Fig 1, respectively). Likewise, two mouse brains were selected for the ter-
tiary (Mo2 and Mo20) and the quaternary (Mo3 and Mo30) passages. The same brain homoge-
nates were also exposed to GT1-7 cells. All intracerebral inoculations were performed under
sevoflurane anesthesia. Three-week-old outbred ICR mice (SLC, Shizuoka, Japan) were inocu-
lated intracerebrally with 20 μL of 10% mouse brain homogenates (2 mg brain equivalent) or
GT1-7 cell homogenates (2 × 105 cells). These homogenates were serially diluted before use.
Mice were checked daily for the presence of clinical signs, such as emaciation, rough fur,
hunched posture, and polyuria. All challenged mice were sacrificed under sevoflurane anesthe-
sia when they presented with clinical disease. Survival period was determined as the time from
inoculation to the clinical endpoint or sudden death, at which point brains were collected for
analysis. The left hemispheres were immediately stored at −80˚C for bioassay and western
blot (WB) analysis, and the right hemispheres were fixed with 10% neutral-buffered formalin
(pH 7.4) containing 10% methanol for histopathology and immunohistochemistry. Prion
Specific prion propagation in GT1-7 cells
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phenotypes were assessed in diseased mice according to survival period and/or neuroanatomi-
cal PrPSc distribution patterns [5].
Exposure of GT1-7 cells to brain homogenates from scrapie-infected
mice
Subcultured GT1-7 cells were exposed to brain homogenates of diseased mice as described
previously [5]. Briefly, cells were grown on 6-well plates at 105 cells/well. After 2 days of incu-
bation, the medium was replaced with 1 mL medium containing 20 μL of 10% (w/v) brain
homogenate as mentioned in the above section. GT1-7 cells exposed to each brain homogenate
are referred as GT/Mo1, GT/Mo2, GT/Mo3, GT/Mo10, GT/Mo20, and GT/Mo30. For tissue
cell culture endpoint titration assay, cells were exposed to 1 mL medium containing 20 μL of
10-fold serial dilutions of brain homogenate. Another 1 mL of plain medium was added to
each well, and cells were incubated for an additional day. Then, the medium was removed, and
the cells were washed three times with serum-free medium and seeded into new 6-well plates
for the first passage (P1). For subsequent passages, cells were seeded in a new well at a 1:4 dilu-
tion every 4 or 5 days, and the remaining cells were cultured in T25 flasks for evaluation of
PrPSc by WB. Each passage and assay was performed twice until the 10th passage (P10).
Extraction of PrPSc from brains and cells
Brain homogenates (20%) were mixed with an equal volume of detergent buffer containing 4%
(w/v) Zwittergent 3–14 (Merck Japan, Tokyo, Japan), 1% (w/v) Sarkosyl (Sigma-Aldrich
Fig 1. Passage history of scrapie sources used in this study. For the serial passage of scrapie prions in
mice, the brain of a single mouse was chosen from the previous passage. The selected mice were named
Mo1, Mo2, and Mo3 in Exp. 1 and Mo10, Mo20, and Mo30 in Exp. 2. Mice that clinically and/or pathologically
developed L-type disease are shown in grey, while those that developed S-type disease are shown in white.
Survival days are indicated underneath each mouse. PrPSc-positive and -negative GT1-7 cells are shown in
grey and white, respectively.
https://doi.org/10.1371/journal.pone.0179317.g001
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Japan, Tokyo, Japan), 100 mM NaCl, and 50 mM Tris-HCl (pH 7.6) and were incubated for
30 min with collagenase (Wako, Osaka, Japan; final concentration of 500 μg/mL) at 37˚C. To
detect PrPSc in GT1-7 cells, confluent cells were washed with phosphate-buffered saline (PBS)
and then lysed with lysis buffer containing 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 0.5%
(w/v) Triton X-100, 0.5% (w/v) sodium deoxycholate, and 2 mM EDTA. After 2 min of centri-
fugation at 6,500 ×g at 4˚C, the supernatant was collected. Then, samples prepared from brains
and cells were incubated for 30 min with proteinase K (PK) (Roche Diagnosis Japan, Tokyo,
Japan; final concentration of 40 μg/mL) at 37˚C. PK digestion was terminated with 2 mM 4-
(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (Pefabloc; Roche Diagnostics Japan).
Samples were mixed with a 2-butanol/methanol mixture (5:1), and PrPSc was precipitated by
centrifugation at 20,000 ×g for 10 min at 20˚C. Pellets were resuspended in Laemmli sample
buffer and subjected to WB.
Immunoprecipitation
Before immunoprecipitation, concentrations of infected brain homogenates were adjusted to
contain approximately the same amount of PK-resistant PrPSc according to the intensities of
the bands obtained by WB. Infected brain homogenates were mixed with brain homogenates
prepared from PrP knockout mice to normalize the amount of total protein in each sample.
Then, normalized brain homogenates were lysed with an equal volume of buffer containing
0.01% (w/v) Triton X-100, 0.01% (w/v) sodium deoxycholate, 100 mM NaCl, and 10 mM Tris-
HCl (pH 7.6) for a final concentration of 5% (w/v). After vortexing, lysed brain homogenates
were centrifuged at 500 ×g for 15 min at 4˚C, and the supernatants were collected. Then,
supernatants were diluted to a final concentration of 0.5% (w/v) with buffer containing 3%
(w/v) Tween 20 and 3% (w/v) Triton X-100 in PBS. Protein G Dynabeads (Life Technologies
Japan, Tokyo, Japan) were blocked with 4% (w/v) blocking solution (BlockAce; DS Pharma
Biomedical, Osaka, Japan). Diluted supernatants (250 μL) were incubated with PrPSc-specific
monoclonal antibody (mAb) 3H6 [12, 13] at a concentration of 1 μg/mL in 500-μL reaction
volumes for 2.5 h with rotation at room temperature. Protein G Dynabeads (40 μL) were
added and incubated for 2 h on the rotor at room temperature. Beads were washed five times
with PBS containing 2% (w/v) Tween 20 and 2% (w/v) Triton X-100. Then, beads were resus-
pended in Laemmli sample buffer and subjected to WB.
Western blotting
Samples were electrophoresed on NuPAGE Novex 12% Bis-Tris gels with NuPAGE
MOPS-SDS running buffer in accordance with the manufacturer’s instructions (Life Technol-
ogies, Carlsbad, CA, USA). Proteins were transferred onto an Immobilon-P membrane (Milli-
pore, Billerica, MA, USA). The blotted membrane was incubated with anti-PrP mAb T2-HRP
[14] at 4˚C overnight. After washing twice with PBS containing 0.05% (v/v) Tween 20
(PBS-T), signals were developed with a chemiluminescent substrate (SuperSignal; Thermo
Fisher Scientific K.K., Yokohama, Japan). For semi-quantitation, blots were imaged using a
Fluorchem system (Alpha Innotech, San Leandro, CA, USA) and analyzed using image reader
software (AlphaEaseFC; Alpha Innotech) according to the manufacturer’s instructions.
Histopathology and immunohistochemistry
Formalin-fixed brains were immersed in 98% formic acid to reduce infectivity and then
embedded in paraffin wax. Serial sections were stained with hematoxylin and eosin for evalua-
tion of neuropathological changes. After epitope retrieval, PrPSc immunocytochemistry was
performed using the mAbs T1 [14] or SAF84 (Bertin Pharma, Montigny le Bretonneux,
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France) [15]. Immunoreactions were developed using the anti-mouse universal immunoper-
oxidase polymer [Nichirei Histofine Simple Stain MAX-PO (M); Nichirei, Tokyo, Japan] as
the secondary antibody and were visualized with 3,30-diaminobenzedine tetrachloride as the
chromogen.
Results
Susceptibility of GT1-7 cells to scrapie prions during interspecies
transmission
As shown in Fig 1, GT1-7 cells produced de novo PrPSc in response to exposure to primary pas-
saged scrapie (Kanagawa)-infected mouse brains in two sets of transmission experiments
(Fig 1, Exp. 1 and Exp. 2). However, GT1-7 cells did not produce de novo PrPSc following expo-
sure to Mo2 and Mo3 brains in Exp. 1 (Fig 1, Exp. 1 and S1 Fig). In contrast, de novo PrPSc was
detected in GT1-7 cells exposed to Mo20 and Mo30 brains in Exp. 2 (Fig 1, Exp. 2 and S1 Fig).
To resolve the discrepancy between the two experiments, accumulated prions in the brains
and GT1-7 cells were analyzed.
Heterogeneity of prions in mice infected with sheep Kanagawa scrapie
isolate
As shown in Exp. 2 of Fig 1 and Table 1, mice challenged with the brain homogenates of the
sheep scrapie Kanagawa case exhibited L-type disease from the primary to 3rd passages.
Because of the species barrier, survival periods in the primary passaged mice were long;
Table 1. Infection of mice with L- and S-type prions with or without passaging in GT1-7 cells.
Inoculum 1 PrPSc in inoculum 2 Subsequent passages in mice
n/n0 3 Survival days 4 Prion phenotype
Exp. 1 6 Mo1 brain (463 days, L-type) 5 + 8/9 196 ± 31.6 S-type
1/9 289 L-type
GT1-7 exposed to Mo1 brain + 9/9 278 ± 5.7 L-type
Mo2 brain (251 days, S-type) + 10/10 148 ± 8.9 S-type
GT1-7 exposed to Mo2 – 8/9 288 ± 36.8 S-type
1/9 375 L-type
Mo3 brain (150 days, S-type) + 5/5 143 ± 4.3 S-type
GT1-7 exposed to Mo3 brain – 9/9 246 ±17.6 S-type
Exp. 2 Mo1’ brain (469 days, L-type) + 5/10 220 ± 7.2 S-type
5/10 290 ± 6.4 L-type
GT1-7 exposed to Mo1’ brain + 9/9 285 ± 15.4 L-type
Mo2’ brain (295 days, L-type) + 1/11 195 S-type
10/11 273 ±13.8 L-type
GT1-7 exposed to Mo2’ brain + 9/9 277±14.7 L-type
Mo3’ brain (276 days, L-type) + 5/5 191 ± 7.1 S-type
GT1-7 exposed to Mo3’ brain + 10/10 280 ± 13.1 L-type
1 Inoculum (brain or GT1-7 cells) was intracerebrally injected into ICR mice.
2 PrPSc accumulation was confirmed by western blotting: +, PrPSc positive;–, PrPSc negative.
3 Number of diseased mice out of total number of challenged mice.
4 Survival periods were determined as the time from inoculation to the clinical endpoint or death (mean survival days ± standard deviation).
5 Survival periods and prion phenotype of the individual mouse used for the inoculation are indicated.
6 Experiment numbers are the same as in Fig 1.
https://doi.org/10.1371/journal.pone.0179317.t001
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therefore, disease phenotype was determined by the neuroanatomical PrPSc distribution pat-
terns of their brains. In contrast to Exp. 2, the disease phenotype changed from L-type to S-
type in Exp. 1 at the 2nd passage. As shown in Fig 2A, mice that developed S-type disease accu-
mulated PK-resistant PrPSc more rapidly than mice that developed the L-type disease. Weak
PrPSc signals bound to mAb 3H6 were detected in the primary passaged mouse brains in both
experiments. The intensity of the PrPSc signal bound to mAb 3H6 was clearly elevated in the
brains of mice that developed S-type disease at the 2nd and subsequent passages (Fig 2B, lanes
2–4). In contrast, PrPSc signals bound to mAb 3H6 in the brains of mice that developed L-type
disease remained weak at the 2nd passage (Fig 2B, lane 6), but the signal intensities gradually
increased at the 3rd passage (Fig 2B, lane 7). Lane 8 in Fig 2 shows a mouse whose disease phe-
notype changed from L-type to S-type at the 4th passage, and its survival period was shortened
to 181 days. Both PK-resistant and mAb 3H6-specific PrPSc signal intensities of this mouse
were clearly higher than those detected in the previous passage in Exp. 2. These results may
indicate that heterogeneous prions were present in a single mouse challenged with the brain
homogenates of scrapie-affected sheep Kanagawa.
Fig 2. Monitoring PrPSc accumulation in diseased mice throughout passaging. (A) Representative
western blot of PrPSc in mouse brains at different passages. Experiment number, survival days, passage
number, disease phenotype, and lane number are indicated on the top of the panel. Each lane included 0.2
mg brain equivalents. (B) Immunoprecipitation assay with mAb 3H6. Lane number is indicated on the top of
the panel. In lane 9, uninfected brain homogenate was probed with mAb 3H6. In all other lanes, PrPSc was
detected with mAb T2-HRP. Molecular markers are shown on the left side of each panel.
https://doi.org/10.1371/journal.pone.0179317.g002
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Disease phenotypes of mice challenged with PrPSc-positive and
PrPSc-negative GT1-7 cells
To determine whether the biological properties of L- and S-type prions were maintained after
serial passages in GT1-7 cell culture, brain homogenates collected from the mice that devel-
oped L-type or S-type disease at each passage number were exposed to cells and subcultured
until passage #10 (P10), and then these cells were intracerebrally injected into ICR mice. WB
analysis demonstrated that GT1-7 cells exposed to the brain homogenates from mice that
developed L-type disease harbored PrPSc, while the cells exposed to the brain homogenates
from mice that developed S-type disease did not (S1 Fig). All mice challenged with PrPSc-
positive GT1-7 cells developed L-type disease with a 100% attack rate (Table 1 and Fig 3) and
had similar mean survival periods (277–285 days) when 10% brain homogenates were inocu-
lated (273–290 days) as shown in Table 1. Of the mice challenged with PrPSc-negative GT1-7
cells, only one mouse developed L-type disease (2nd passage of Exp. 1 in Table 1 and Fig 3I and
3J), and the others developed S-type disease with longer incubation periods (2nd and 3rd pas-
sages of Exp. 1 in Table 1 and Fig 3G and 3H) as compared to those of mice inoculated with
10% brain homogenates of S-type-diseased mice (Ka/W column of mouse bioassay in Table 2).
A clear difference in the glycoprofiles of PrPSc was not observed between mice challenged with
mouse-passaged and cell-passaged prions (Fig 4). These results indicate that the biological fea-
tures of L-type prions can be sustained in PrPSc-positive GT1-7 cells after serial passages. How-
ever, the PrPSc glycoprofiles of L-type prion-infected GT1-7 cells were clearly different from
those of the brains (Fig 4 and S2 Fig), indicating the involvement of not only prion strains (iso-
lates) but also host cellular factors in the PrPSc glycoform ratio.
Endpoint titration assays of L-type and S-type scrapie prions in GT1-7
cells and ICR mice
To compare the susceptibility to L-type and S-type prions between conventional mice and
GT1-7 cells, serial dilutions of L- or S-type prion-infected mouse brain homogenates were
used to challenge to ICR mice and GT1-7 cells, respectively (Table 2). Because of the heteroge-
neity in mouse-passaged L-type scrapie isolates, the Tsukuba-2 mouse-passaged scrapie isolate,
which was purified by limiting dilution, was used as a substitute for Ka/O isolates. GT1-7 cells
exposed to a 10−5 dilution of brain homogenate from a mouse that developed L-type disease
produced de novo PrPSc in 1 out of the 2 wells; however, they did not produce de novo PrPSc in
response to a 10−6 dilution (Table 2 and S2 Fig). Prion titers of the tested brain were estimated
at 106.7 TCID50/g of brain equivalents (eq). A bioassay using ICR mice challenged with the
same dilutions demonstrated that 1 out of the 5 mice clinically and pathologically developed
L-type disease in response to the injection of a 10−5 dilution, indicating that the tested brain
contained 106.3 LD50/g of brain eq (Table 2). In contrast, 3 out of the 5 mice challenged with a
10−7 dilution of S-type prion-infected brain homogenate developed S-type disease, indicating
that this brain contained 108.8 LD50/g of brain eq of S-type prions. However, no PrP
Sc was
detected from GT1-7 cells exposed to the same dilutions or even from those exposed to a 10−1
dilution (Table 2).
Discussion
At the primary passage, extremely long incubation periods are commonly observed during
interspecies transmission. This results from the species barrier. It is well known that incuba-
tion periods and neuropathological features are stabilized after a few passages in the same
mouse strains [16]. In contrast, it has been reported that the scrapie disease phenotype,
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including incubation periods, clinical signs, and neuropathology, can suddenly change, even
after serial passages in the same mouse strain [17, 18]. This phenomenon is called “break-
down”, and it was observed at the 4th passage of L-type prions in this study (Table 1 and Fig 5).
Interestingly, we found that the PrPSc-specific mAb 3H6 preferred to be bound to the PrPSc
that accumulated in mice that developed S-type disease according to immunoprecipitation
Fig 3. Representative images of PrPSc deposition types associated with each prion phenotype in ICR mice. Sections of the hippocampus
were subjected to immunostaining of PrPSc and H&E staining. Typical PrPSc distribution patterns and histopathology of the hippocampus affected
with L-type (A and B) and S-type (C and D) prions are shown. Sections of the hippocampi of mice inoculated with cell homogenates prepared from
GT/Mo1 (E and F), GT/Mo2 (G, H, I and J), GT/Mo3 (K and L), GT/Mo1 0 (M and N), GT/Mo20 (O and P), and GT/Mo30 (Q and R) were also
subjected to immunostaining of PrPSc and H&E staining. Immunohistochemical detection of PrPSc was performed using the mAb SAF84.
https://doi.org/10.1371/journal.pone.0179317.g003
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assays. The amount of PrPSc bound to mAb 3H6 in a mouse brain selected from the 3rd passage
of L-type prions (lane 7 in Fig 2B) tended to be higher than that of the brains selected from
previous passages (lanes 5 and 6 in Fig 2B), and the mice inoculated with this brain exhibited
breakdown at the 4th passage. These data strongly suggest that the proportions of L- and S-type
prions in the brain are altered during serial transmission in mice. In addition, mouse endpoint
titration assays for both S- and L-type prions enable us to speculate that S-type prions repli-
cated faster than L-type prions in mice, as mice that received 102.8 infectious units of S-type
prions developed the disease earlier than those that received 106.4 infectious units of L-type pri-
ons (Table 2). This indicates the possibility that S-type prions easily become dominant
throughout subsequent passages in mice when both prions co-exist in a single mouse brain.
Experimental mice are routinely used to amplify scrapie prions. We propose that close atten-
tion must be paid in order to maintain L-type prions in laboratory mice. In contrast to mice,
GT1-7 cells efficiently amplify PrPSc and sustain high prion infectivity in response to L-type
prions but not to S-type prions. Moreover, the biological properties of L-type prions remain
unchanged after serial passages in GT1-7 cells. Taken together, this cell culture model could be
convenient for the stable amplification of L-type prions.
It requires over 280 days to obtain the bioassay results regarding L-type prions even when
mice are challenged with 10% brain homogenates. However, using PrPSc accumulation as an
index, GT1-7 cell culture assay could produce results in approximately 60 to 70 days. In addi-
tion, the sensitivity of tissue cell culture assay to L-type prions was comparable to that of
mouse bioassay. In contrast, the amplification of S-type prions in GT1-7 cells was extremely
inefficient (Table 2). An unexpected finding of this study was that the mice challenged with
PrPSc-negative GT1-7 cells developed S-type disease (2nd and 3rd passages in Exp. 1 of Table 1).
These cells were subcultured more than 10 times before injection into mice. It is likely that the
original brain homogenate exposed to GT1-7 cells was diluted to a level below the detection
Table 2. Comparison of the susceptibility of GT1-7 cells and ICR mice to L- and S-type prions.
Assay GT1-7 at P10 1 ICR mice 2
PrPSc accumulation Survival periods (n/n0) 3
Isolate (Phenotype 4) Ka/O (L-type) Ka/W (S-type) Tsukuba-2 (L-type) Ka/W (S-type)
Log10 dilution of inoculum 7 -1 + + 5 – – 288 ± 5.0 (4/4) 147 ± 3.8 (5/5)
-2 + + N.D 6 326 ± 32.8 (5/5) 155 ± 3.1 (5/5)
-3 + + N.D 355 ± 22.1 (3/3) 168 ± 3.4 (5/5)
-4 + + N.D 461 ± 21.5 (4/4) 177 ± 2.9 (5/5)
-5 + – N.D 496 (1/5) 194 ± 4.8 (5/5)
-6 – – N.D >496 (0/5) 246 ± 13.8 (5/5)
-7 N.D N.D >496 (0/5) 203, 234, 235 (3/5)
-8 N.D N.D >496 (0/5) >496 (0/5)
Infectious units 8 106.7 TICD50 N.D 106.4 LD50 108.8 LD50
1 PrPSc accumulation in GT1-7 cells was investigated at 10th passage (P10).
2 Mouse endpoint titration assay was conducted.
3 Survival periods are shown as mean survival days ± standard deviation. Number of diseased mice out of total number of inoculated mice is shown as n/n0.
4 Prion phenotypes are indicated.
5 PrPSc accumulation was confirmed by western blotting: +, PrPSc positive;–, PrPSc negative. Results of duplicate wells are indicated.
6 No data.
7 Mouse brain homogenate was diluted from 10−1 to 10−8. 10−1 indicates 10% brain homogenate.
8 Infectious units (TCID50 or LD50 per gram of brain equivalents) were calculated by Behrens-Karber’s formula.
https://doi.org/10.1371/journal.pone.0179317.t002
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limit of the mouse bioassay; that is, we cannot exclude the possibility that very low levels of
S-type prions continue to replicate even in PrPSc-positive GT1-7 cells. Further study will be
needed to resolve this issue. Nevertheless, we here demonstrated that the susceptibility of GT1-
7 cells to L-type prions was at least 105 times higher than that to S-type prions. We conclude
that GT1-7 cells would be useful for the selective propagation of L-type prions. Recently, the
relationship between the seeding activity of PrPSc and prion infectivity has been revealed
through the use of protein misfolding cyclic amplification (PMCA) and real-time quaking-
induced conversion (RT-QuIC) [19–22]. Therefore, combining the tissue cell culture assays
developed here with PMCA and/or RT-QuIC may provide new opportunities for the purifica-
tion of L-type prions from a mixed prion population.
It remains unclear why L-type prions are efficiently amplified in GT1-7 cells, unlike in the
mouse brain. One possibility is that conformational differences between L- and S-type prions
directly affect their effective replication in GT1-7 cells. Indeed, our immunoprecipitation
assays may indicate that L-type prions have structurally different PrPSc conformations from
S-type prions. The other possibility is that host-encoded cofactors, which may be lacking in
GT1-7 cells, are required for the efficient replication of S-type prions. Previous reports done
by others also support the selective susceptibility of neuronal populations in animals and in
cell culture models to specific prion strains or isolates [23–27]. Our data may suggest the possi-
bility that prion strain-specific cofactors are differentially expressed among various cells.
Fig 4. Glycoform profiles of PrPSc in mice infected with GT1-7 cell culture-derived S-type and L-type prions. PrPSc glycoform
percentages of original mouse brains used for the infection of GT1-7 cells (Mo1, Mo2, Mo3, Mo10, Mo20, and Mo30) were compared to
those of mouse brains inoculated with GT1-7 cell homogenates (GT/Mo1, GT/Mo2, GT/Mo3, GT/Mo10, GT/Mo20, and GT/Mo30).
Results of GT1-7 cell homogenate-inoculated mice are shown as the mean ± standard deviation (n = 4). The PrPSc glycoprofile of GT/
Mo2-inoculated mice in this graph shows the mean glycoform ratio of the mice that developed S-type disease. The inoculum (brain or
GT1-7 cells) was intracerebrally injected into ICR mice. Experiment numbers are the same as in Fig 1.bar graph shows di-
glycosylated (black columns), mono-glycosylated (gray columns), and unglycosylated (white columns) forms of PrPSc. L- and S-type
at the bottom of each lane indicate the disease phenotypes. PrPSc was detected with mAb T2-HRP.
https://doi.org/10.1371/journal.pone.0179317.g004
Specific prion propagation in GT1-7 cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0179317 June 21, 2017 10 / 14
Cofactors for prion replication, such as phospholipids and polyanions, have been mainly iden-
tified in in vitro PrPSc amplification studies [28–30]. Further study is required to clarify the
cofactors that are clearly involved in the effective replication of specific prions in in vivo
models.
Supporting information
S1 Fig. Susceptibility of GT1-7 cells to diseased brains taken from different mouse pas-
sages. Representative western blot of GT1-7 cells exposed to diseased brains derived from dif-
ferent mouse passages (1st to 3rd). Experiment number, passage number, protein loaded (μg),
and lane number are indicated at the top of each lane. GT1-7 cells were collected at P10, and
PrPSc was detected with mAb T2-HRP. Mr indicates the protein marker. Molecular markers
are shown on the left. Three laboratory scrapie prion strains (22L, ME7, and Chandler) were
used as positive and negative infection controls. As previously reported [5], GT1-7 cells were
susceptible to 22L and Chandler but not to ME7.
(TIF)
S2 Fig. PrPSc glycoprofiles of GT1-7 cells infected with L-type prion. Glycoform ratios of
GT1-7 cells exposed to Mo30 brain homogenates were calculated at passage #8 (P8) and #10
(P10). PrPSc was detected with mAb T2-HRP. The bar graph shows di-glycosylated (black
Fig 5. Illustration of breakdown during the transmission of L-type prions in mice and effective
amplification in GT1-7 cells. Grey mice and cells indicate the presence of L-type prions, while white mice and
cells indicate S-type prions. Mice exhibiting the L-type disease still harbor S-type scrapie prions, resulting in
the appearance of mice with the S-type disease at every passage from P2 to P4. GT1-7 cells accumulate
PrPSc in response to L-type prions and can be used to re-propagate mice with L-type prions by injecting mice
with cell homogenates. In contrast, GT1-7 cells challenged with S-type prions do not accumulate PrPSc, but
they do harbor very low levels of S-type prion infectivity.
https://doi.org/10.1371/journal.pone.0179317.g005
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columns), mono-glycosylated (gray columns), and unglycosylated (white columns) forms of
PrPSc. Values are expressed as the mean ± standard deviation (n = 3).
(TIF)
S3 Fig. Tissue cell culture endpoint titration assay of GT1-7 cells exposed to brain homoge-
nates of passage 3 mice exhibiting the L-type disease. Representative western blot of GT1-7
cells exposed to serial dilutions of brain homogenates from mice with the L-type disease phe-
notype at P10. Isolate name and prion phenotype of the inoculum are indicated at the top. The
log10 dilution factor of the brain homogenate and the amount of protein loaded (μg) are also
indicated at the top of each lane. PrPSc was detected with mAb T2-HRP. Molecular markers
are shown on the left.
(TIF)
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